Opportunity
SAM #75N98026Q00677
NIH Solicitation for Whole Exome Sequencing Using AmpliSeq Exome and ION Platform
Buyer
NIH Office of Logistics and Acquisition Operations
Posted
June 22, 2026
Respond By
July 02, 2026
Identifier
75N98026Q00677
NAICS
541715, 325414, 541714
The National Institutes of Health (NIH), Office of Logistics and Acquisition Operations (OLAO), under the Department of Health and Human Services, is seeking specialized whole exome analysis services for the NIAAA Clinical Center patient cohort. - Government Buyer: - Department of Health and Human Services (HHS) - National Institutes of Health (NIH) - Office of Logistics and Acquisition Operations (OLAO) - OEMs and Vendors: - Life Technologies, Inc. (OEM for AmpliSeq Exome and ION Sequencing Platform) - Products/Services Requested: - Whole exome sequencing analysis service - Must use AmpliSeq Exome enrichment system - Sequencing must be performed on the ION sequencing platform - Unique or Notable Requirements: - Consistency with previous analyses for over 2,000 patients, all performed using the same AmpliSeq Exome and ION platform combination - No substitutions or alternative platforms permitted to ensure data comparability and analytical integrity - No specific part numbers or product quantities provided; focus is on the service using the specified platforms
Description
The NIAAA Clinical Center patient cohort has been analyzed patients for sequence variant differences, and changes in response to treatment over the course of many years as part of an effort to identify underlying causes of alcohol related disorders. Analysis has previously been performed on over 2000 patients using the AmpliSeq Exome enrichment system and sequenced on the ION sequencing platform because it provides the capability of cost-effective high throughput whole-exome genome-wide analysis. The use of a single enrichment and sequencing platform with consistent information content is essential for analysis of samples screened at different times and it is therefore imperative for analytical integrity that all samples in the study are processed on the same sequencing platform, as each platform has a unique pattern of error